Konstantinos Leventakos

The Genomic Landscape and Treatment Outcomes Associated with CDKN2A/MTAP Loss in Patients with Non–Small Cell Lung Cancer

Natalie I. Vokes, Jessica L. Symons, Brooke Rhead, Lingzhi Hong et autres

INTRODUCTION: Homozygous deletion of 9p21, containing CDKN2A/B and MTAP (CMdel), underlies emerging therapeutic strategies including PRMT5/MAT2A inhibition. The clinicogenomic context and treatment outcomes of CMdel in NSCLC remain incompletely defined. METHODS: We analyzed Tempus Lens records with paired DNA/RNA sequencing. After quality …

us, br, nl, sg (code pays fourni par la source)

Lightweight Retrieval-Augmented Generation and Large Language Model-Based Modeling for Scalable Patient-Trial Matching

Xiaodi Li, Yang Xiao, MunHwan Lee, Konstantinos Leventakos et autres

Patient-trial matching requires reasoning over long, heterogeneous electronic health records (EHRs) and complex eligibility criteria, posing significant challenges for scalability, generalization, and computational efficiency. Existing approaches either rely on full-document processing with large language models (LLMs), which is computationally expensive, or use …

Lightweight Retrieval-Augmented Generation and Large Language Model-Based Modeling for Scalable Patient-Trial Matching

Xiaodi Li, Yang Xiao, MunHwan Lee, Konstantinos Leventakos et autres

Patient-trial matching requires reasoning over long, heterogeneous electronic health records (EHRs) and complex eligibility criteria, posing significant challenges for scalability, generalization, and computational efficiency. Existing approaches either rely on full-document processing with large language models (LLMs), which is computationally expensive, or use …

us (code pays fourni par la source)

Abstract 449: Albumin-based DLL3-targeted nano-immunoconjugates of SN38 preserve potency and demonstrate high-affinity DLL3 binding in small cell lung cancer.

Mohamed Shanshal, Lin Yang, Liyi Geng, W. Nevala et autres

Abstract Background: Small cell lung cancer (SCLC) remains an aggressive malignancy with limited treatment options and a 5-year survival rate under 10%. Delta-like ligand 3 (DLL3), expressed in >85% of SCLC but absent from normal tissue, represents an attractive therapeutic target. Existing …

us (code pays fourni par la source)

Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.

Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma et autres

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received …

us (code pays fourni par la source)

Abstract 2446: High PRMT5 expression is associated with decreased immune infiltrate and worse outcomes to immune checkpoint inhibitors in non-small cell lung cancer

N. Vokes, Stamatina Fragkogianni, Pooja A. Shah, Santiago G. Trevino et autres

Abstract Background: Deletions in MTAP occur in 10-15% of cancers and are associated with poor prognosis. MTAP deletion (MTAPdel) leads to accumulation of MTA which causes partial inhibition of PRMT5, creating a synthetic lethality approach with PRMT5 inhibitors. Multiple investigational MTA-cooperative PRMT5 …

us (code pays fourni par la source)

89O BMS-986504 with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007

B. George, Konstantinos Leventakos, M. Pelster, J. Rodon Ahnert et autres

In the phase 1 CA240-0007 study, BMS-986504 (MTA-cooperative PRMT5 inhibitor) was well tolerated and had antitumor activity in pts with MTAP-del advanced solid tumors, including PDAC. Here, we report updated clinical outcomes with BMS-986504 monotherapy and initial efficacy and safety data for …

us, de, se, gb, it (code pays fourni par la source)

Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial

Benjamin Levy, Luis Paz-Ares, Chien-Chung Lin, Scott Herbert et autres

INTRODUCTION: The phase Ib two-part (dose escalation and expansion) six-cohort TROPION-Lung02 study evaluated datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum-based chemotherapy (Pt-CT) in patients with advanced or metastatic NSCLC without actionable genomic alterations. METHODS: ) once every 3 weeks. The …

us, es, tw, jp, it (code pays fourni par la source)

Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support

Ryan M. Brown, Katie E. Smith, Mohammed Shanshal, Anastasios Dimou et autres

us (code pays fourni par la source)

Supplemental Figure 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher et autres

Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results.ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.

Supplemental Figure 4 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher et autres

Supplemental Figure 4: Radiographic response of patients that cleared their plasma (teal) at cycle 4 versus that did not (red).

Supplementary Data 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher et autres

Demographics and Baseline Characteristics